申请人:Dainippon Sumitomo Pharma Co., Ltd.
公开号:EP1939202A1
公开(公告)日:2008-07-02
An adenine compound useful for a medicament represented by the following formula (1):
, wherein A1 and A2 are independently, optionally substituted cyclic aromatic hydrocarbon group or optionally substituted aromatic heterocyclic group;
L1, L2 and L3 are independently, alkylene or a single optionally substituted alkylene or a single bond, and any methylene or methyne in L2 or L3 may be bound with N atom adjacent to L2 and L3 to form 4 to 7 membered saturated hetero ring containing N atom;
L4 is alkylene or a single bond;
R1 is optionally substituted alkyl group, optionally substituted alkenyl group, optionally substituted aryl group, etc.;
R2 is hydrogen atom or optionally substituted alkyl group;
R3 is optionally substituted alkyl group, etc.;
X is oxygen atom, etc.;
or its pharmaceutically acceptable salt.
一种腺嘌呤化合物,可用于下式(1)所代表的药物:
其中 A1 和 A2 独立地为任选取代的环状芳香烃基团或任选取代的芳香杂环基团;
L1、L2 和 L3 独立地为亚烷基或单个任选取代的亚烷基或单键,L2 或 L3 中的任何亚甲基或甲基可与 L2 和 L3 相邻的 N 原子结合,形成含有 N 原子的 4 至 7 个成员的饱和杂环;
L4 是亚烷基或单键;
R1 是任选取代的烷基、任选取代的烯基、任选取代的芳基等;
R2 是氢原子或任选取代的烷基;
R3 是任选取代的烷基等;
X 是氧原子等;
或其药学上可接受的盐。